SG11202110546UA - Formulation for oral delivery of proteins, peptides and small molecules with poor permeability - Google Patents

Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Info

Publication number
SG11202110546UA
SG11202110546UA SG11202110546UA SG11202110546UA SG11202110546UA SG 11202110546U A SG11202110546U A SG 11202110546UA SG 11202110546U A SG11202110546U A SG 11202110546UA SG 11202110546U A SG11202110546U A SG 11202110546UA SG 11202110546U A SG11202110546U A SG 11202110546UA
Authority
SG
Singapore
Prior art keywords
peptides
proteins
formulation
small molecules
oral delivery
Prior art date
Application number
SG11202110546UA
Inventor
Vincent Plassat
Benoit Hilbold
Aurélia Galus
Thomas Pointeaux
Julien Meissonnier
Original Assignee
R P Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R P Scherer Technologies Llc filed Critical R P Scherer Technologies Llc
Publication of SG11202110546UA publication Critical patent/SG11202110546UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
SG11202110546UA 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability SG11202110546UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832508P 2019-04-11 2019-04-11
PCT/US2020/027801 WO2020210723A1 (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Publications (1)

Publication Number Publication Date
SG11202110546UA true SG11202110546UA (en) 2021-10-28

Family

ID=70476554

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202110546UA SG11202110546UA (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
SG11202111251SA SG11202111251SA (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202111251SA SG11202111251SA (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Country Status (16)

Country Link
US (3) US20220249468A1 (en)
EP (2) EP3952899A1 (en)
JP (2) JP2022526833A (en)
KR (2) KR20210151187A (en)
CN (2) CN113784722A (en)
AR (1) AR118654A1 (en)
AU (2) AU2020270985A1 (en)
BR (1) BR112021018817A2 (en)
CA (2) CA3134550A1 (en)
CO (2) CO2021012462A2 (en)
EA (2) EA202192793A1 (en)
IL (2) IL287084A (en)
MX (2) MX2021012354A (en)
SG (2) SG11202110546UA (en)
WO (2) WO2020210723A1 (en)
ZA (1) ZA202108909B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116456981A (en) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 Compositions for improved GRP inhibitor delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
EP0684834A4 (en) * 1993-02-17 1996-09-25 Smithkline Beecham Corp Microemulsions comprising therapeutic peptides.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
FR2803203B1 (en) * 1999-12-31 2002-05-10 Fournier Ind & Sante NEW GALENIC FORMULATIONS OF FENOFIBRATE
CA2439366A1 (en) 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
ATE424815T1 (en) 2001-12-03 2009-03-15 Dor Biopharma Inc STABILIZED REVERSE MICELLAR COMPOSITIONS AND USE THEREOF
JP4490809B2 (en) 2002-06-05 2010-06-30 ブリストル−マイヤーズ スクイブ カンパニー Calcitonin gene-related peptide receptor antagonist
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
CN101048137A (en) * 2004-10-29 2007-10-03 诺瓦提斯公司 Spontaneously dispersible pharmaceutical compositions
AU2005309808A1 (en) 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
EP2063708A2 (en) * 2006-09-08 2009-06-03 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
AU2008244523B2 (en) * 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
RU2010113979A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) USE OF BUBUC AND OPTIONAL EAA-MARTI (26-35) AS A THERAPEUTIC FOR THE TREATMENT OF HCMV INFECTIONS
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2011073408A2 (en) 2009-12-18 2011-06-23 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US8481546B2 (en) 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
BR112014028600B1 (en) * 2012-05-18 2022-11-22 Genentech, Inc SUSPENSION FORMULATIONS COMPRISING HIGH CONCENTRATION MONOCLONAL ANTIBODY, ITS METHOD OF PREPARATION, ITS USE AND DEVICE FOR SUBCUTANEOUS ADMINISTRATION, AND METHOD FOR PRODUCING AN ARTICLE OF MANUFACTURING
CA2898408C (en) 2013-02-28 2018-01-02 Pfizer Inc. Enhanced stability of novel liquid compositions
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
EP3142699A4 (en) * 2014-05-16 2017-11-22 Salk Institute for Biological Studies Compositions and methods for treating metabolic disorders
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins

Also Published As

Publication number Publication date
IL287131A (en) 2021-12-01
SG11202111251SA (en) 2021-11-29
EP3952899A1 (en) 2022-02-16
AU2020272059A1 (en) 2021-12-09
KR20210151185A (en) 2021-12-13
JP2022526196A (en) 2022-05-23
CO2021014899A2 (en) 2021-11-19
MX2021012356A (en) 2021-11-04
AR118654A1 (en) 2021-10-20
TW202103726A (en) 2021-02-01
US20200323985A1 (en) 2020-10-15
CN113784722A (en) 2021-12-10
US20220143188A1 (en) 2022-05-12
WO2020210722A1 (en) 2020-10-15
EP3952900A1 (en) 2022-02-16
MX2021012354A (en) 2021-10-22
CO2021012462A2 (en) 2021-09-30
CN113966223A (en) 2022-01-21
US20220249468A1 (en) 2022-08-11
EA202192793A1 (en) 2022-01-12
JP2022526833A (en) 2022-05-26
US11185589B2 (en) 2021-11-30
BR112021018817A2 (en) 2021-11-23
EA202192792A1 (en) 2022-01-11
CA3136485A1 (en) 2020-10-15
IL287084A (en) 2021-12-01
KR20210151187A (en) 2021-12-13
AU2020270985A1 (en) 2021-12-09
WO2020210723A1 (en) 2020-10-15
CA3134550A1 (en) 2020-10-15
ZA202108909B (en) 2022-07-27

Similar Documents

Publication Publication Date Title
IL276715A (en) Compositions and methods for membrane protein delivery
IL276464A (en) Methods and compositions for therapeutic protein delivery
EP3623389A4 (en) Fusion protein containing tgf- receptor and medicinal uses thereof
EP3906055A4 (en) Multi-specific protein molecules and uses thereof
SA518390954B1 (en) Therapeutic HPV18 Vaccines
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
ZA202000491B (en) Peptide amide compounds, preparation method thereof and use in medicine
EP3908835A4 (en) Single-molecule protein and peptide sequencing
EP3490538A4 (en) Particles for delivery of proteins and peptides
EP3964531A4 (en) Protein molecule and use thereof
MX2016015594A (en) Improved peptide pharmaceuticals for insulin resistance.
EP3362048A4 (en) Composition for intraoral delivery of biologically active peptides and proteins
EP3639845A4 (en) Il-15 protein complex pharmaceutical composition and uses thereof
EP3186272A4 (en) Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same
EP3542824A4 (en) Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
EP3875471A4 (en) Respiratory syncytial virus recombinant f protein and vaccine composition containing same
ZA202108909B (en) Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
EP3313379A4 (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
IL283229A (en) High concentration protein formulation
EP4067495A4 (en) Mrna construct for protein expression, and use thereof
IL238101A (en) Method for preparation of n-acyl peptides, polypeptides and proteins
EP3569613A4 (en) Erythropoietin-derived peptide, preparation method therefor, and use thereof
EP3318572A4 (en) Composition comprising amino acid and cyclic dipeptide
EP3932912A4 (en) Protein and/or peptide modification molecule
EP3474826A4 (en) Pharmaceutical preparation for delivery of peptides and proteins